Elevated plasma sVCAM‐1 levels in children with sickle cell disease: Impact of chronic transfusion therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Vascular cell adhesion molecule‐1 (VCAM‐1) has been implicated as being important in the pathophysiology of acute pain episodes (APE) and acute chest syndrome (ACS) of sickle cell disease (SCD). The frequency of these episodes is reduced by chronic transfusion therapy. The impact of chronic transfusion therapy on VCAM‐1 expression is unknown. Soluble VCAM‐1 (sVCAM‐1) levels were measured in plasma using an ELISA assay (R&D Systems) in 61 patients with SCD (age range 1.5–20 years) and 12 normal controls (2.5–14 years). SCD patients included 20 with ACS, 14 with APE, 12 at well‐child visits, and 15 receiving chronic transfusion therapy. Asymptomatic SCD patients had higher sVCAM‐1 levels compared to normal subjects (P < 0.001). Levels of sVCAM‐1 were further elevated during ACS (P < 0.001) and APE (P = 0.072) and returned to the asymptomatic range on resolution. Levels were significantly lower in transfused patients (P = 0.003) compared to asymptomatic SCD patients. Our findings of increased VCAM‐1 expression during ACS and perhaps APE offer a rationale for therapeutic use of cytokine and other VCAM‐1 modulators. The reduction of sVCAM‐1 levels observed in our transfused SCD patients offers insight into the mechanism of the protective effect of transfusion against ACS and APE and possibly stroke. Am. J. Hematol. 76:57–60, 2004. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“High steady-state WBC counts in SCD patients are associated with recurrent pain [20], acute chest syndrome [21], stroke [22], early death [23,24], and other adverse events [25].”
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546 · cited 1×
“High steady-state WBC counts in SCD patients are associated with recurrent pain [20], acute chest syndrome [21], stroke [22], early death [23,24], and other adverse events [25].”
Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course
Vichinsky, E. P., Styles, L. A., Colangelo, L. H., Wright, E. C., Castro, O., Nickerson, B., & Disease, T. C. S. O. S. C. (1997) · Blood · doi:10.1182/blood.v89.5.1787 · Cited by 573
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508 · cited 1×
“High steady-state WBC counts in SCD patients are associated with recurrent pain [20], acute chest syndrome [21], stroke [22], early death [23,24], and other adverse events [25].”
Self-citationStroke in a cohort of patients with homozygous sickle cell disease
Balkaran, B., Char, G., Morris, J. S., Thomas, P. W., Serjeant, B. E., & Serjeant, G. R. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80897-2 · Cited by 419
Cited by
Daily Assessment of Pain in Adults with Sickle Cell Disease
Smith, W. R., Penberthy, L. T., Bovbjerg, V. E., McClish, D. K., Roberts, J. D., Dahman, B., Aisiku, I. P., Levenson, J. L., & Roseff, S. D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00004 · Cited by 648
Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa050460 · Cited by 635
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Morris, C. R. (2008) · Hematology · doi:10.1182/asheducation-2008.1.177 · Cited by 194
Autonomic reactivity and clinical severity in children with sickle cell disease
Pearson, S. R., Alkon, A., Treadwell, M., Wolff, B., Quirolo, K., & Boyce, W. T. (2005) · Clinical Autonomic Research · doi:10.1007/s10286-005-0300-9 · Cited by 68
Kwiatkowski, J. L., Yim, E., Miller, S., Adams, R. J., & for the STOP 2 Study Investigators (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22951 · Cited by 49
“leukocyte/endothelial interactions and is thought to contribute to vasculopathy, also are lower in transfused compared with nontransfused patients with SCD at steady state [9].”
Self-citation
Metadata
- Authors
- Sakhalkar, V. S., Rao, S. P., Weedon, J., & Miller, S. T.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2004-05
- Volume
- 76
- Issue
- 1
- Pages
- 57-60
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1990447822
- Cited by
- 41
- References
- 6
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated plasma sVCAM‐1 levels in children with sickle cell disease: Impact of chronic transfusion therapy. https://app.cochat.ai/papers/10.1002/ajh.20016
- The paper
- Sakhalkar, V. S., Rao, S. P., Weedon, J., & Miller, S. T. (2004). Elevated plasma sVCAM‐1 levels in children with sickle cell disease: Impact of chronic transfusion therapy. American Journal of Hematology. https://doi.org/10.1002/ajh.20016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.